Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CAPOXIRI in Pancreatic Adenocarcinoma
NCT01760252Phase 2Terminated
- Sponsor
- Mount Sinai Beth Israel
- Start
- Dec 2011
- Primary completion
- Feb 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and irinotecan in pancreatic adenocarcinoma (PDAC), sponsored by Mount Sinai Beth Israel. Primary endpoint: Treatment Adherence Rate at 5 years. Started Dec 2011; status: terminated.
02
Drugs
capecitabineoxaliplatinirinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01760252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01760252.